GSK unveils 3‑year cost‑saving plan to fund late‑stage R&D and move research HQ to Cambridge from AZ”,

British drugmaker GSK has unveiled a three-year, £1.9 billion ($2.5 billion) cost‑saving programme targeting annual savings by 2029, aimed at funding late‑stage R&D and pipeline development.

The plan, called the "Accelerate Growth" programme, will generate savings mainly through procurement efficiencies, reallocating resources from mature to specialty products, and streamlining support functions and the site network, with total one‑time costs of about £2.4 billion.

Most of the savings will be reinvested into the late‑stage portfolio, including assets in oncology, respiratory, hepatology and vaccines, while part will shore up margins around the 2028–2030 dolutegravir patent‑expiry period.

As part of the strategy, GSK is moving its research headquarters from Stevenage to a new £400 million R&D hub on the Cambridge Biomedical Campus, integrating into the academic and biotech ecosystem; the Stevenage site will be vacated by 2029 and nearby Ware upgraded, shifting around 1,000 scientists.